van Hooren, Luuk http://orcid.org/0000-0002-0780-5827
Vaccaro, Alessandra
Ramachandran, Mohanraj
Vazaios, Konstantinos
Libard, Sylwia
van de Walle, Tiarne
Georganaki, Maria
Huang, Hua
Pietilä, Ilkka
Lau, Joey http://orcid.org/0000-0002-8302-3253
Ulvmar, Maria H.
Karlsson, Mikael C. I. http://orcid.org/0000-0001-5582-614X
Zetterling, Maria
Mangsbo, Sara M.
Jakola, Asgeir S.
Olsson Bontell, Thomas
Smits, Anja
Essand, Magnus http://orcid.org/0000-0002-9725-0422
Dimberg, Anna http://orcid.org/0000-0003-4422-9125
Funding for this research was provided by:
Cancerfonden (CAN 2017/502, 20 1008 PjF, 20 1010 UsF, CAN 2015/1216)
Barncancerfonden (PR2015-0133, NCP2015-0075, PR2018-0148, TJ 2017-0004, TJ 2019-0014)
Vetenskapsrådet (Dnr 2016-02495)
Knut och Alice Wallenbergs Stiftelse (KAW 2019.0088)
Emil och Wera Cornells Stiftelse (NA)
Svenska Sällskapet för Medicinsk Forskning (S15-0065)
Article History
Received: 28 January 2021
Accepted: 9 June 2021
First Online: 5 July 2021
Competing interests
: S.M.M. is the founder and shareholder of Immuneed AB and Vivologica AB and is the Chief Development Officer and shareholder of Ultimovacs ASA/AB. None of the mentioned companies have taken part in the study nor do they have a financial gain of the specific subject matter described herein. The other authors declare no competing interests.